WHO's antibacterial pipeline reports

WHO annually analyzes the pipeline for agents that target bacteria (antibacterials) to facilitate the setting of priorities for R&D.

WHO's antibacterial pipeline reports - The Lancet Infectious Diseases

The antibacterial pipeline report details preclinical and clinical studies of traditional and novel antibacterial agents worldwide. It offers an assessment of ...

2023 Antibacterial agents in clinical and preclinical development

Overview · All of the data contained in this report can be downloaded from the WHO Global Observatory on Health R&D: · WHO R&D and pipeline ...

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Based on these summaries, you will not be surprised by the report's sobering main conclusion: “Overall, antibacterial agents in the clinical ...

WHO's antibacterial pipeline reports - PubMed

WHO's antibacterial pipeline reports. Lancet Infect Dis. 2022 Oct;22(10):1424. doi: 10.1016/S1473-3099(22)00603-X. Author. Vijay Shankar Balakrishnan. PMID ...

insights from WHO 2023 antibacterial clinical pipeline analyses

However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research.

WHO's antibacterial pipeline reports - AMR Insights

WHO's antibacterial pipeline reports ... The antibacterial pipeline report details preclinical and clinical studies of traditional and novel ...

Multi-year analysis of the global preclinical antibacterial pipeline

To understand the status of upstream antibiotic development and the challenges faced by drug developers in the early development stage, the ...

Antibiotics in the clinical pipeline as of December 2022 - Nature

... antibiotic resistance project was discontinued in December 2021 [28]. In 2022, the WHO published a report on antibacterial agents in both ...

Antibiotic pipeline not active enough to fight deadliest bacteria, WHO ...

The report, the first published since 2017, assesses whether antibiotics in the pipeline will likely address infections caused by WHO priority pathogens.

The global preclinical antibacterial pipeline - Nature

A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline ...

The Global Preclinical Antibacterial Pipeline | ASM.org

The process for review of the antibacterial pipeline, the progress and gaps in antibiotic discovery and the opportunities to overcome the ...

Exploring the Global Clinical and Preclinical Antibacterial Pipelines

According to the WHO report published in 2021, the global clinical pipeline currently includes 43 conventional antibiotics and 27 non- ...

WHO calls antibiotic pipeline insufficient - CIDRAP

The World Health Organization (WHO) is issuing new warnings about the state of the antibiotic development pipeline. In two reports issued ...

“Time is running out”: WHO review warns there are not enough ...

A World Health Organization (WHO) review has warned that there are too few antibiotics in the pipeline to tackle critical pathogens, ...

From resistance to resilience: what could the future antibiotic ...

In a new report, we review the antibiotic pipeline data against bacterial pathogens identified by the WHO and other public health agencies as of the greatest ...

Tracking the Pipeline of Antibiotics in Development

To shed light on the pipeline, evaluate public policies, and monitor the potential impact on public health, The Pew Charitable Trusts tracked products in ...

Antibiotics under development insufficient to tackle antimicrobial ...

Discover the latest analysis of antibacterial agents under development worldwide by WHO, evaluating the pipeline's effectiveness against ...

Tracking the Global Pipeline of Antibiotics in Development, March ...

In December 2021, Pew's antibiotic resistance project discontinued its work tracking antibiotics and nontraditional products in global ...

WHO Report: Antibacterial Agents in Clinical and Preclinical ...

The WHO's latest report on antibacterial agents reveals a rise in the clinical pipeline, but emphasizes the urgent need for new, ...